Measurement of Ocular Blood Flow and Retinal Oxygen Extraction in Diabetic Patients

NCT07536516 · Recruiting

Last updated 2026-05-28

This clinical trial measures eye blood flow and oxygen levels in people with diabetes to study changes in their eyes.

Status Recruiting Currently enrolling participants.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design open-label (no blinding) diagnostic study

Participants 20 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-11 · est. completion 2026-06

Where 1 site · Austria

What this study is testing ClinicalTrials.gov NCT07536516 ↗

Description as written by the study sponsor.

The prevalence of diabetes is increasing, with type 2 diabetes mellitus comprising over 90% of cases. Diabetes mellitus complications, including diabetic retinopathy (DR), impose significant health burdens. GLP-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 receptor agonists show promise in improving cardiovascular and kidney outcomes, but their effects on retinal microvasculature and neuroprotection remain unclear. This study investigates the impact of GLP-1RAs (semaglutide, liraglutide) and GIP/GLP-1-dual agonists (tirzepatide) on ocular blood flow and retinal function in DM patients.

Treatments tested

• Laser Speckle Flowgraphy (LSFG) Device

Laser Speckle Flowgraphy (LSFG)
• Optical Coherence Tomography (OCT) Device

• Optical Coherence Tomography (OCT)
• Optical Coherence Tomography Angiography (OCT-A) Device

• Optical Coherence Tomography Angiography (OCT-A)

Main thing measured	Ocular blood flow (LSFG)
Sponsor	Medical University of Vienna
Conditions studied	Diabetes Mellitus
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07536516 ↗